Does caplacizumab, used for treatment of thrombotic thrombocytopenic purpura (TTP), correct ADAMTS13 deficiency or eliminate anti-ADAMTS13 autoantibodies?

Caplacizumab does not affect ADAMTS levels or ADAMTS13 antibody production. It is an anti–von Willebrand factor humanized, bivalent variable-domain-only immunoglobulin fragment that inhibits interaction between von Willebrand factor multimers and platelets.